Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

Similar articles for PubMed (Select 8707496)

1.

Influences on the quality of published drug studies.

Bero LA, Rennie D.

Int J Technol Assess Health Care. 1996 Spring;12(2):209-37. Review.

PMID:
8707496
2.

Funding source, trial outcome and reporting quality: are they related? Results of a pilot study.

Clifford TJ, Barrowman NJ, Moher D.

BMC Health Serv Res. 2002 Sep 4;2(1):18.

3.

A randomized study of how physicians interpret research funding disclosures.

Kesselheim AS, Robertson CT, Myers JA, Rose SL, Gillet V, Ross KM, Glynn RJ, Joffe S, Avorn J.

N Engl J Med. 2012 Sep 20;367(12):1119-27.

4.
5.

The quality of drug studies published in symposium proceedings.

Cho MK, Bero LA.

Ann Intern Med. 1996 Mar 1;124(5):485-9.

PMID:
8602706
6.

Association between pharmaceutical involvement and outcomes in breast cancer clinical trials.

Peppercorn J, Blood E, Winer E, Partridge A.

Cancer. 2007 Apr 1;109(7):1239-46.

7.

Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology.

Knox KS, Adams JR, Djulbegovic B, Stinson TJ, Tomor C, Bennet CL.

Ann Oncol. 2000 Dec;11(12):1591-5.

8.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
9.

A framework establishing clear decision criteria for the assessment of drug efficacy.

Huster WJ, Enas GG.

Stat Med. 1998 Aug 15-30;17(15-16):1829-38. Review.

PMID:
9749450
11.

Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions.

Jørgensen AW, Maric KL, Tendal B, Faurschou A, Gøtzsche PC.

BMC Med Res Methodol. 2008 Sep 9;8:60. doi: 10.1186/1471-2288-8-60.

12.

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.

Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C.

Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv. Review.

13.

Issues for statisticians in pharmaco-economic evaluations.

Grieve AP.

Stat Med. 1998 Aug 15-30;17(15-16):1715-23; discussion 1741-3. Review.

PMID:
9749442
14.

Health-related quality of life assessment and the pharmaceutical industry.

Revicki DA, Rothman M, Luce B.

Pharmacoeconomics. 1992 Jun;1(6):394-408.

PMID:
10147021
15.

A contract research organization's response to the new FDA guidances for bioequivalence/bioavailability studies for orally administered drug products.

Kimanani E, Stypinski D, Curtis G, Stiles M, Heessels P, Logan S, Nelson K, St Germain E, Boswell G.

J Clin Pharmacol. 2000 Oct;40(10):1102-8.

PMID:
11028249
16.

Association of industry sponsorship to published outcomes in gastrointestinal clinical research.

Brown A, Kraft D, Schmitz SM, Sharpless V, Martin C, Shah R, Shaheen NJ.

Clin Gastroenterol Hepatol. 2006 Dec;4(12):1445-51. Epub 2006 Nov 13.

PMID:
17101295
17.

Progress and dilemma of contemporary clinical pharmacology.

Herman ZS.

Int J Clin Pharmacol Ther. 2005 Jan;43(1):43-50. Review.

PMID:
15704614
18.
19.
20.

Design, execution, interpretation, and reporting of economic evaluation studies in obstetrics.

Vintzileos AM, Beazoglou T.

Am J Obstet Gynecol. 2004 Oct;191(4):1070-6.

PMID:
15507923
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk